- Home
- ETY vs RDY Comparison
ETY vs RDY Comparison
Compare ETY & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETY
- RDY
- Stock Information
- Founded
- ETY 2006
- RDY 1984
- Country
- ETY United States
- RDY India
- Employees
- ETY N/A
- RDY N/A
- Industry
- ETY Finance Companies
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- ETY Finance
- RDY Health Care
- Exchange
- ETY Nasdaq
- RDY Nasdaq
- Market Cap
- ETY 2.2B
- RDY 2.1B
- IPO Year
- ETY N/A
- RDY N/A
- Fundamental
- Price
- ETY $14.97
- RDY $14.71
- Analyst Decision
- ETY
- RDY Buy
- Analyst Count
- ETY 0
- RDY 1
- Target Price
- ETY N/A
- RDY $17.00
- AVG Volume (30 Days)
- ETY 247.3K
- RDY 1.6M
- Earning Date
- ETY 01-01-0001
- RDY 05-09-2025
- Dividend Yield
- ETY 7.21%
- RDY 0.65%
- EPS Growth
- ETY N/A
- RDY 1.46
- EPS
- ETY N/A
- RDY 0.79
- Revenue
- ETY N/A
- RDY $3,809,801,863.00
- Revenue This Year
- ETY N/A
- RDY $10.24
- Revenue Next Year
- ETY N/A
- RDY N/A
- P/E Ratio
- ETY N/A
- RDY $18.43
- Revenue Growth
- ETY N/A
- RDY 16.61
- 52 Week Low
- ETY $10.59
- RDY $12.26
- 52 Week High
- ETY $13.46
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- ETY 65.23
- RDY 63.81
- Support Level
- ETY $14.48
- RDY $14.24
- Resistance Level
- ETY $14.82
- RDY $14.77
- Average True Range (ATR)
- ETY 0.19
- RDY 0.20
- MACD
- ETY 0.01
- RDY 0.04
- Stochastic Oscillator
- ETY 100.00
- RDY 95.59
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.